Abstract:Protein–protein interactions (PPIs) execute many fundamental cellular functions and have served as prime drug targets over the last two decades. Interfering intracellular PPIs with small molecules has been extremely difficult for larger or flat binding sites, as antibodies cannot cross the cell membrane to reach such target sites. In recent years, peptides smaller size and balance of conformational rigidity and flexibility have made them promising candidates for targeting challenging binding interfaces with satisfactory binding affinity and specificity. Deciphering and characterizing peptide–protein recognition mechanisms is thus central for the invention of peptide-based strategies to interfere with endogenous protein interactions, or improvement of the binding affinity and specificity of existing approaches. Importantly, a variety of computation-aided rational designs for peptide therapeutics have been developed, which aim to deliver comprehensive docking for peptide–protein interaction interfaces. Over 60 peptides have been approved and administrated globally in clinics. Despite this, advances in various docking models are only on the merge of making their contribution to peptide drug development. In this review, we provide (i) a holistic overview of peptide drug development and the fundamental technologies utilized to date, and (ii) an updated review on key developments of computational modeling of peptide–protein interactions (PepPIs) with an aim to assist experimental biologists exploit suitable docking methods to advance peptide interfering strategies against PPIs.

Advancements in Loop Cyclization Approaches for Enhanced Peptide Therapeutics for Targeting Protein-Protein Interactions

Advancements in loop cyclisation approaches for enhanced pep1de therapeutics for targeting protein-protein interactions

Design and Synthetic Strategies for Helical Peptides.

Peptide therapeutics: Targeting the undruggable space

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

A Comprehensive Review on Current Advances in Peptide Drug Development and Design

Protein/peptide secondary structural mimics: design, characterization, and modulation of protein–protein interactions

Designing Cyclic-Constrained Peptides to Inhibit Human Phosphoglycerate Dehydrogenase

Current Synthetic Approaches to Peptide and Peptidomimetic Cyclization

Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives

Therapeutic design of peptide modulators of protein-protein interactions in membranes

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

Cyclic Peptide Linker Design and Optimization by Molecular Dynamics Simulations

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

Polymers for Disrupting Protein-Protein Interactions: Where Are We and Where Should We Be?

Rational design of small-molecule peptidomimetics for three pivotal protein secondary structures

Targeting Protein-Protein Interaction by Small Molecules

Modulators of 14-3-3 Protein–Protein Interactions

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

Computational Modeling as a Tool to Investigate PPI: From Drug Design to Tissue Engineering

Main methods and tools for peptide development based on protein-protein interactions (PPIs)